RENFLEXIS® (Infliximab-abda) a biosimilar to Remicade, is a drug used in the treatment of Inflammatory Bowel Disease, as well as other autoimmune diseases.
RENFLEXIS® is manufactured by Organon.
Administration and Dosage:
It is a weight-based medication following a recommended induction dose of 5mg/kg and maintenance dose of 10mg/kg (per Prescribing Doctor’s recommendation). The medication is infused intravenously in intervals at week 0, 2, 6 and then every 8 weeks for maintenance.
Common Side Effects:
The more common side effects of RENFLEXIS® include risk of infection.
Ready to Schedule an Appointment?
Please CLICK HERE to get started.
RENFLEXIS® is indicated to treat:
- Crohn’s Disease
- Ulcerative Colitis
- Pediatric Ulcerative Colitis
- Pediatric Crohn’s Disease
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Plaque Psoriasis